within Pharmacolibrary.Drugs.ATC.C;

model C07AB02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.0020666666666666667,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0055,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.0045,
    k12             = 91,
    k21             = 91
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07AB02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Metoprolol is a selective β1-adrenergic receptor blocker used primarily to treat high blood pressure, angina, heart failure, and to prevent myocardial infarction. It is widely approved for clinical use and is available in both immediate-release and extended-release formulations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following oral administration of immediate-release metoprolol tartrate.</p><h4>References</h4><ol><li><p>Zamir, A, et al., &amp; Rasool, MF (2022). Clinical Pharmacokinetics of Metoprolol: A Systematic Review. <i>Clinical pharmacokinetics</i> 61(8) 1095–1114. DOI:<a href=\"https://doi.org/10.1007/s40262-022-01145-y\">10.1007/s40262-022-01145-y</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35764772/\">https://pubmed.ncbi.nlm.nih.gov/35764772</a></p></li><li><p>Luethy, D, et al., &amp; Slack, J (2022). Pharmacokinetics and pharmacodynamics of oral and intravenous metoprolol tartrate in clinically healthy horses. <i>Journal of veterinary pharmacology and therapeutics</i> 45(2) 177–187. DOI:<a href=\"https://doi.org/10.1111/jvp.13037\">10.1111/jvp.13037</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34913168/\">https://pubmed.ncbi.nlm.nih.gov/34913168</a></p></li><li><p>Thibault, N, et al., &amp; Turpault, S (2020). Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. <i>Molecular genetics and metabolism</i> 129(4) 278–285. DOI:<a href=\"https://doi.org/10.1016/j.ymgme.2020.01.001\">10.1016/j.ymgme.2020.01.001</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32029355/\">https://pubmed.ncbi.nlm.nih.gov/32029355</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07AB02;
